Evolus Eyes 2027 Sculpt Launch as Filler Portfolio Expands and Revenue Grows
Evolus executives said its expanding injectable aesthetics product lineup is expected to support growth as the company prepares for the anticipated 2027 launch of Evolysse Sculpt.
Why it matters — EOLS watchers may follow the planned Sculpt launch and the role of the expanding product portfolio in supporting company growth.